Somatic symptoms in depression

Dialogues in Clinical Neuroscience

Volumn 8, Issue 2, 2006, Pages 227-239

  Kapfhammer, Hans Peter ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Depression; Neurobiology; Somatic symptom; Treatment

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; DULOXETINE; MILNACIPRAN; MIRTAZAPINE; MODAFINIL; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ANXIETY; CHRONICITY; DEPRESSION; HUMAN; PATIENT CARE; PRIMARY MEDICAL CARE; QUALITY OF LIFE; REVIEW; SUICIDE;

DEPRESSION; HUMANS; PRIMARY HEALTH CARE; PSYCHIATRIC STATUS RATING SCALES; SOMATOFORM DISORDERS;

EID: 33746374295     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (169)

1. Wernicke C. Grundlagen der Psychiatrie. Leipzig, Germany: Thieme; 1906.
2. Dupré E. Les cénestopathies. (transi. Rohde M). In: Hirsch SR, Shepherd M, eds. Themes and Variations in European Psychiatry. Bristol, UK: John Wright; 1974.
3. Schneider K. Die Schichtung des emotionalen Lebens und der Aufbau der Depressionszustände. Z Ges Neurol Psychiatr. 1920;59:281-286.
4. Huber G. Psychiatrie. Lehrbuch für Studium und Weiterbildung. 7th ed. Stuttgart, Germany: Schattauer; 2005.
5. Bleuler M. Die Depressionen in der Allgemeinpraxis. 2nd ed. Basel, Switzerland: Schwabe; 1943;10-11.
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text Revision. Washington, DC: American Psychiatric Press; 2003.
7. Tylee A, Gandhi P. The importance of somatic symptoms in depression in primary care. Prim Care Companion J Clin Psychiatry. 2005;7:167-176.
8. Maier W, Falkai P. The epidemiology of comorbidity between depression, anxiety disorders and somatic diseases. Int Clin Psychopharmacol. 1999;14 (suppl 2):1-6.
9. Kapfhammer HP. Die psychopharmakologische Behandlung von ängstlichdepressiven Syndromen im Kontext somatischer Erkrankungen. In: Möller HJ, ed. Therapie psychiatrischer Erkrankungen. 3rd ed. Stuttgart, Germany: Thieme; 2005.
10. Kapfhammer HP. Behandlung von somatoformen Störungen. In: Möller HJ, ed. Therapie psychiatrischer Erkrankungen. 3rd ed. Stuttgart, Germany: Thieme; 2005.
11. Kroenke K. Somatic symptoms and depression: a double hurt. Prim Care Companion J Clin Psychiatry. 2005;7:148-149.
12. Hamilton M. Frequency of symptoms in melancholia (depressive illness). Br J Psychiatry. 1989;154:201-206.
13. Akiskal HS. Diagnosis and classification of affective disorders: new insights from clinical and laboratory approaches. Psychiatr Dev. 1983;2:123-160.
14. Jones D, Hall SB. Significance of somatic complaints in depression in patients suffering from psychotic depression. Acta Psychotherapeutica. 1963;11:193-199.
15. Hagnell O, Rorsman B. Suicide and endogenous depression with somatic symptoms in the lundby study. Neuropsychobiology. 1978;4:180-187.
16. ESEMeD/MHEDEA 2000 Investigators. Disability and quality of life impact of mental disorders in Europe: Results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand. 2004;109 (suppl 1):47-54.
17. Katon WJ, Unützer J, Simon G. Treatment of depression in primary care. Where we are, where we can go. Med Care. 2004;42:1153-1157.
18. Lépine JP, Gastpar M, Mendlewitz J, Tyee A, on behalf of the DEPRES Steering Committee Depression in the community (Depression Research in European Society). Int Clin Psychopharmacol 1997;12:19-29.
19. Wittchen HU, Höfler M, Meister W. Depressionen in der Allgemeinpraxis. Die bundesweite Depressionsstudie. Stuttgart, Germany: Schattauer; 2000.
20. Paykel ES, Brugha T, Fryers T. Size and burden of depressive disorders in Europe. Eur Neuropsychopharmacol. 2005;15:411-423.
21. Kirmayer LJ, Groleau D, Looper KJ, Dao MD. Explaining medically unexplained symptoms. Can J Psychiatry. 2004;49:663-672.
22. Kroenke K. The interface between physical and psychological symptoms. Prim Care Companion J Clin Psychiatry. 2003;5:11-18.
23. Tylee A, Gastpar M, Lepine JP, et al. DEPRES II (Depression research in European society II): a patient survey of the symptoms, disability, and current management of depression in the community. DEPRES Steering Commitee. Int Clin Psychopharmacol. 1999;14:139-151.
24. Simon G.E, Korff von M, Piccinelli M, et al. An international study of the relation between somatic symptoms and depression. N Engl J Med. 1999;341:1329-1335.
25. Kirmayer LJ, Robbins JM, Dworking M, et al. Somatisation and the recognition of depression and anxiety in primary care. Am J Psychiatry. 1993;150:734-741.
26. Bair MJ, Robinson RL, Katon W, et al. Depression and pain comorbidity: a literature review. Arch Intern Med. 2003;163:2433-2445.
27. Khan AA, Khan A, Harezlak J, et al. Somatic symptoms in primary care: etiology and outcome. Psychosomatic. 2003;44:471-478.
28. Kroenke K, Mangelsdorff AD. Common symptoms in ambulatory care: incidence, evaluation, therapy, and outcome. Am J Med. 1989;86:262-266.
29. Kroenke K. Patients presenting with somatic complaints: epidemiology, psychiatric comorbidity, and management. Int J Methods Psychiatr Res. 2003;12:34-43.
30. Kisely S, Goldberg D, Simon G. A comparison between somatic symptoms with and without clear organic cause: results of an international study. Psychol Med. 1997;27:1011-1019.
31. Kroenke K, Spitzer RL, Williams JBW, et al. Physical symptoms in primary care: predictors of psychiatric disorders and functional impairment. Arch Fam Med. 1994;3:774-779.
32. Reid S, Wessely S, Crayford T, et al. Medically unexplained symptoms in frequent attenders of secondary health care: retrospective cohort study. BMJ. 2001;322:767.
33. Spitzer RL, Kroenke K, Williams JBW. Validation and utility of a self report version of PRIME-MD: the PHQ primary care study. JAMA. 1999;282:1737-1744.
34. Gerber PD, Barrett JE, Barrett JA, et al. The relationship of presenting physical complaints to depressive symptoms in primary care patients. J Gen Intern Med. 1992;7:170-173.
35. Aaron LA, Buchwald D. A review of the evidence for overlap among unexplained clinical conditions. Ann Intern Med. 2001;134:868-881.
36. Wesseley S, White PD. There is only one functional somatic syndrome. Br J Psychiatry. 2004;185:95-96.
37. Manu P, ed. Functional Somatic Syndromes. Etiology, Diagnosis and Treatment. Cambridge, UK: Cambridge University Press; 1988,32-57.
38. Deary IJ. A taxonomy of medically unexplained symptoms. J Psychosom Res. 1999;47:51-59.
39. Henningsen P, Zimmermann T, Sattel H. Medically unexplained physical symptoms, anxiety and depression: a meta-analytic review. Psychosom Med. 2003;65:528-533.
40. Hudson JI, Mangweth B, Pope HG, et al. Family study of affective spectrum disorder. Arch Gen Psychiatry. 2003;60:170-177.
41. Robbins JM, Kirmayer LJ, Hemami S. Latent variable models of functional somatic distress. J Nerv Ment Dis. 1997;22:551-564.
42. Gureje O, Simon G. E, Von Korff M. A cross-national study of the course of persistent pain in primary care. Pain. 2001;92:195-200.
43. Lépine JP, Briley M. The epidemiology of pain in depression. Hum Psychopharmacol Clin Exp. 2004;19:3-7.
44. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients: results from the Medical Outcomes Study. JAMA. 1989;262:914-919.
45. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-psychiatric disorders in the United States: Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8-19.
46. Regier DA, Myers JK, Kramer M, et al. The NIMH Epidemiologic Catchment Area program: historical context, major objectives, and study population characteristics. Arch Gen Psychiatry. 1984;41:934-941.
47. Kroenke K, Price RK. Symptoms in the community: prevalence, classification, and psychiatric comorbidity. Arch Intern Med. 1993;153:2474-2480.
48. Magni G, Marchetti M, Moreschi C, Merskey H, Luchini SR. Chronic musculoskeletal pain and depressive symptoms in the National Health and Nutrition Examination, I: epidemiologic follow-up study. Pain. 1993;53.163-168.
49. Ohayon MM, Schatzberg AF. Using chronic pain to predict depressive morbidity in the general population. Arch Gen Psychiatry. 2003;60:39-47.
50. Katon W. Diagnosis: relationship to somatization and chronic medical illness. J Clin Psychiatry. 1984;45. 4-12.
51. De Waal MWM, Arnold IA, Eekhof AJH, Van Hemert AM. Somatoform disorders in general practice. Br J Psychiatry. 2004;184:470-476.
52. De Waal MWM, Arnold IA, Spinhoven P, et al. The reporting of specific physical symptoms for mental distress in general practice. J Psychosom Res. 2005;59:89-95.
53. Dickinson WP, Dickinson ML, deGruy FV, et al. The somatization in primary care study: a tale of three diagnoses. Gen Hosp Psychiatry. 2003;25:1-7.
54. Haug TT, Mykletun A, Dahl AA. The association between anxiety, depression, and somatic symptoms in a large population: the HUNT-II study. Psychosom Med. 2004;66(suppl 6):845-851.
55. Jacobi F, Wittchen HU, Hölting C, et al. Prevalence, comorbidity and correlates of mental disorders in the general population: Results from the German Health Interview and Examination Survey (GHS). Psychol Med. 2004;34:597-611.
56. Maier W. Angst- und Somatisierungsstörungen. Fortschr Neurol Psychiat. 1998;66 (suppl 1):3-8.
57. Peveler R, Kilkenny L, Kinmonth AL. Medically unexplained physical symptoms in primary care: a comparison of selfreport screening questionnaires and clinical opinion. J Psychosom Res. 1997;42:245-252.
58. Smith RC, Gardiner J.C, Lyles JS, et al. Exploration of DSM-IV criteria in primary care patients with medically unexplained symptoms. Psychosom Med. 2005;67:123-129.
59. Kroenke K, Jackson J.L, Chamberlin J. Depressive and anxiety disorders in patients presenting with physical complaints: clinical predictors and outcome. Am J Med. 1997;103:339-347.
60. Katon W, Lin E, Von Korff M, et al. Somatization: a spectrum of severity. Am J Psychiatry. 1991;148:34-40.
61. Katon W, Sullivan M, Walker E. Medical symptoms without identified pathology: relationship to psychiatric disorder, childhood and adult trauma, and personality traits. Ann Intern Med. 2001;134:917-925.
62. Möller HJ, Demyttenaere K, Sacchetti E, Rush AJ, Montgomery SA. Improving the chance of recovery from the short- and long-term consequences of depression. Int Clin Psychopharmacol. 2003;18:21-225.
63. Yates WR, Mitchel J, Rush AJ, et al. Clinical features of depressed out-patients with and without co-occurring general medical conditions in STAR*D. Gen Hosp Psychiatry. 2004;26 (suppl 6):421-429.
64. Susser M. Disease, illness, sickness: impairment, disability and handicap. Psychol Med. 1990;20:471-473.
65. Simon G, von Korff M. Medical co-morbidity and validity of DSM-IV depression criteria. Psychol Med. 2005;35:1-10.
66. Wilhelm K, Kotze B, Waterhouse M, et al. Screening for depression in the medically ill: a comparison of self-report measures, clinician judgement, and DSM-IV diagnoses. Psychosomatics. 2004;45:461-469.
67. Yates WR. Epidemiology of psychiatric disorders in the medically ill. In: Robinson RG, Yates WR, eds. Psychiatric Treatment of the Medically III. New York, NY; Basel, Switzerland: Marcel Dekker; 1999;41-64.
68. Fryers T, Melzer D, Jenkins R. Social inequalities and the common mental disorders. A systematic review of the evidence. Soc Psychiatry Psychiatr Epidemiol. 2003;38:229-237.
69. Weich S, Lewis G, Donmall R, Mann A. Somatic presentation of psychiatric morbidity in general practice. Br J Gen Pract. 1995;45:143-147.
70. Nuyen J, Vokers AC, Verhaak PFM, et al. Accuracy of diagnosing depression in primary care: the impact of chronic somatic and psychiatric co-morbidity. Psychol Med. 2005;35:1185-1195.
71. Drayer RA, Mulsant BH, Lenze EJ, et al. Somatic symptoms of depression in elderly patients with medical comorbidities. Int J Geriatr Psychiatry. 2005;20:973-982.
72. Bridges KW, Goldberg DP. Somatic presentation of DSM III psychiatric disorder in primary care. J Psychosom Res. 1985;29:563-569.
73. Schuyler D. Depression comes in many disguises to the providers of primary care: recognition and management. J S C Med Assoc. 2000;96:267-275.
74. Kessler D, Bennewith O, Lewis G, et al. Detection of depression and anxiety in primary care: follow up study. BMJ. 2002;325:1016-1017.
75. Kirmayer LJ, Robbins JM. Patients who somatize in primary care: a longitudinal study of cognitive and social characteristics. Psychol Med. 1996;26:937-957.
76. Barkow K, Heun R, Ustun TB, et al. Identification of items which predict later development of depression in primary health care. Eur Arch Psychiatry Clin Neurosci. 2001;25 (suppl 2):21-26.
77. Berardi D, Menchetti M, Cervenini N, Scaini S, De Ronchi D. Increased recognition of depression in primary casre. Comparison between primary-care physician and ICD-10 diagnosis of depression. Psychother Psychosom. 2005;74:225-230.
78. Henkel V, Mergl R, Coyne JC, et al. Depression with atypical features in a sample of primary care outpatients: Prevalence, specific characteristics and consequences. J Affect Disord. 2004;83:237-242.
79. Wittchen HU, Pittrow D. Prevalence, recognition and management of depression in primary care in Germany: the Depression 2000 study. Hum Psychopharmacol Clin Exp. 2002;17:51-511.
80. Kirmayer LJ, Robbins JM. Three forms of somatization in primary care: prevalence, co-occurrence, and sociodemographic characteristics. J Nerv Ment Dis. 1991;179:645-655.
81. Linden M, Maier W, Achberger M, et al. Psychische Erkrankungen und ihre Behandlung in Allgemeinpraxen in Deutschland. Nervenarzt. 1996;67:205-215.
82. Lloyd GG. Psychiatric syndromes with a somatic presentation. J Psychosom Res. 1986;30:113-120.
83. Kapfhammer HP. Geschlechtsdifferenzielle Perspektive auf somatoforme Störungen. Psychiatrie & Psychotherapie. 2005;1:21-32.
84. Silverstein B. Gender difference in the prevalence of clinical depression: the role played by depression associated with somatic symptoms. Am J Psychiatry. 1999;156:480-482
85. Silverstein B. Gender differences in the prevalence of somatic versus pure depression: a replication. Am J Psychiatry. 2002;159:1051-1052.
86. Wenzel A, Steer RA, Beck AT. Are there any gender differences in frequency of self-reported somatic symptoms of depression? J Affect Disord. 2005;89:177-181.
87. Kroenke K, Spitzer R. Gender differences in the reporting of physical and somatoform symptoms. Psychosom Med. 1998;60:150-155.
88. Jackson JL, Chamberlin J, Kroenke K. Gender and symptoms in primary care practices. Psychosomatics. 2003;44:359-366.
89. Sandanger I, Nygard J.F, Sorensen T, Moum T. Is women's mental health more susceptible than men's to the influence of surrounding stress. Soc Psychiatry Psychiatr Epidemiol. 2004;39:177-184.
90. Stahl SM. Antidepressants and somatic symptoms: therapeutic actions are expanding beyond affective spectrum disorders to functional somatic syndromes. J Clin Psychiatry. 2003;64:7.
91. Craig TKJ, Boardman AP, Mills K, et al. The South London somatization study I: Longitudinal course and the influence of early life experiences. Br J Psychiatry. 1993;163:570-588.
92. Rief W, Martin A, Klaiberg A, Brähler E. Specific effects of depression, panic and somatic symptoms on illness behavior. Psychosom Med. 2005;67:596-601.
93. Henningsen P, Jakobsen T, Schiltenwolf M, Weiss MG. Somatization revisited diagnosis and perceived causes of common mental disorders. J Nerv Mental Dis. 2005;193:85-92.
94. Rief W, Nake A, Emmerich J, Bender A, Zecht T. Causal illness attributions in somatoform disorders: associations with comorbidity and illness behavior. J Psychosom Res. 2004;57(suppl 4):367-371.
95. Sayar K, Kirmayer LJ, Taillefer SS. Predictors of somatic symptoms in depressive disorder. Gen Hosp Psychiatry. 2003;25:108-114.
96. Rief W, Hiller W, Geissner E, Fichter MM. A two-year follow-up study of patients with somatoform disorders. Psychosomatics. 1995;36:376-386.
97. Alper K, Devinsky O, Vasquez B, et al. Non-epileptic seizures and childhood sexual and physical abuse. Neurology. 1993;43:1950-1953.
98. Kapfhammer HP, Rothenhäusler HB. Malingering/Münchhausen: Factitious and somatoform disorders in neurology and clinical medicine. In: Hallett M, Fahn S, Jankovic J, Lang AE, Clonnger CR, Yudofsky SC, eds. Psychogenic Movement Disorders. Neurology and Neuropsychiatry. Philadelphia, Pa: Lippicott Williams & Wilkins; 2005;154-162.
99. Coryell W, Norten SG. Briquet's syndrome (somatization disorder) and primary depression: comparison of background and outcome. Compr Psychiatry. 1981;22:249-256.
100. Drossman DA, Leserman J, Nachman G, et al. Sexual and physical abuse in women with functional or organic gastrointestinal disorders. Ann Intern Med. 1990;113:828-833.
101. Golding JM. Sexual assault history and physical health in randomly selected Los Angeles women. Health Psychol. 1994;13:130-138.
102. Morrison J. Childhood sexual histories of women with somatization disorder. Am J Psychiatry. 1989;146:239-241.
103. Walker EA, Katon WJ, Hansom J, et al. Medical and psychiatric symptoms in women with childhood sexual abuse. Psychosom Med. 1992;54:658-664.
104. Walker EA, Katon W, Harrop-Griffiths J, et al. Relationship of chronic pelvic pain to psychiatric diagnoses and childhood sexual abuse. Am J Psychiatry. 1988;145:75-80
105. Walker EA, Gelfand AN, Gelfand MD, et al. Chronic pelvic pain and gynecological symptoms in women with irritable bowel syndrome. J Psychosom Obstet Gynecol. 1996;17:39-46.
106. Walker EA, Gelfand A, Katon W, et al. Adult health status of women with histories of childhood abuse and neglect. Am J Med. 1999;107:332-339.
107. Barsky AJ, Wool C, Barnett MC, et al. Histories of childhood trauma in adult hypochondriacal patients. Am J Psychiatry. 1994;151:397-401.
108. Kendler KS, Bulik CM, Silberg J, et al. Childhood sexual abuse and adult psychiatric and substance disorders in women: An epidemiological and cotwin control analysis. Arch Gen Psychiatry. 2000;57:953-959.
109. Nelson EC, Heath AC, Madden PA, et al. Associations between self-reported childhood sexual abuse and adverse psychosocial outcomes. Arch Gen Psychiatry. 2002;59:139-145.
110. Wise L, Zierler S, Krieger N, et al. Adult onset of major depressive disorder in relation to childhood and adolescent violence victimization: a case-control study. Lancet. 2001;358:881-887.
111. Arnow BA. Relationships between childhood maltreatment, adult health and psychiatric outcomes, and medical utilization. J Clin Psychiatry. 2004;65(suppl 12):10-15.
112. Stewart DE. Physical symptoms of depression: unmet need in special populations. J Clin Psychiatry. 2003;64(suppl 7):12-16.
113. Almeida Fleck de MP, Simon G, Herrman H, et al. Major depression and its correlates in primary care settings in six countries. Br J Psychiatry. 2005;186:41-47.
114. Keller MB, Hirschfeld RMA, Demyttenaere K, Baldwin DS. Optimizing outcomes in depression: Focus on antidepressant compliance. Int Clin Psychopharmacol. 2002;17:265-271.
115. Fava M. The role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression. J Clin Psychiatry. 2003;64 (suppl 13):26-29.
116. Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord. 1998;50:97-108.
117. Judd LL, Martin P, Schettler PJ, et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness. Am J Psychiatry. 2000;157:1501-1504.
118. Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995;25:1171-1180.
119. Kennedy N, Paykel ES. Residual symptoms at remission from depression: impact on long-term outcome. J Affect Disord. 2004;80:135-144.
120. Fishbain DA. The relationship of chronic pain and suicide. Sem Clin Neuropsychiatry. 1999;4:221-227.
121. Korff von M, Simon G. The relationship between pain and depression. Br J Psychiatry 1996;168:101-108.
122. Bair MJ, Robinson RL, Eckert GJ, et al. Impact of pain on depression treatment response in primary care. Psychosom Med. 2004;66:17-22.
123. Karp JF, Scott J, Houck P, et al. Pain predicts longer time to remission during treatment of recurrent depression. J Clin Psychiatry. 2005;66(suppl 5):591-597
124. Simon Gregory E, Korff von M, Lin E. Clinical and functional outcomes of depression treatment in patients with and without chronic. Psychol Med. 2005;35:271-279.
125. Bao Y, Sturm R, Croghan TW. A national study of the effect of chronic pain on the use of health care by depressed persons. Psychiatr Serv. 2003;54:693-697.
126. Barsky AJ, Orav EJ, Bates DW. Somatization increases medical utilization and costs independent of psychiatric and medical comorbidity. Arch Gen Psychiatry. 2005;62:903-910.
127. Luber MP, Meyers BS, Williams-Russo PG, et al. Depression and service utilization in elderly primary care patients. Am J Geriatr Psychiatry. 2001;9:169-176.
128. Keeley R, Smith M, Miller J. Somatoform symptoms and treatment non-adherence in depressed family medicine outpatients. Arch Fam Med. 2000;9:46-54.
129. O'Leary D, Paykel ES, Todd C, Vardulaki K. Suicide in primary affective disorders revisited: a systematic review by treatment era. J Clin Psychiatry. 2001;62:804-811.
130. Abbas M, Hotopf M, Prince M. Depression and mortality in a high-risk population: 1-year follow-up of the Medical Research Council Elderly Hypertension trial. Br J Psychiatry. 2000;181:123-128.
131. Angst F, Stassen HH, Clayton PJ, et al. Mortality of patients with mood disorder: follow-up over 34-38 years. J Affect Disord. 2002;68:167-181.
132. Penninx BWJH, Beekman ATF, Honig A, et al. Depression and cardiac mortality: Results from a community-based longitudinal survey. Arch Gen Psychiatry. 2001;58:221-227.
133. Greden JF. Physical symptoms of depression: unmet needs. J Clin Psychiatry. 2003;64 (suppl 7):5-11.
134. Greenberg PE, Leong SA, Birnbaum HG, et al. The economic burden of depression with painful symptoms. J Clin Psychiatry. 2003;64 (suppl 7):17-23.
135. Fifer SK, Buesching DP, Henke G, et al. Functional status and somatization as predictors of medical offset in anxious and depressed patients. Value Health. 2003;6:40-50.
136. Doraiswamy PM, Khan ZM, Donahue RM, et al. Quality of life in geriatric depression: a comparison of remitters, partial responders, and nonresponders. Am J Geriatr Psychiatry. 2001;9:423-428.
137. Nemeroff CB, Vale WW. The neurobiology of depression: inroads to treatment and new drug discovery. J Clin Psychiatry. 2005;66(suppl 7):5-13.
138. Stahl SM. The psychopharmacology of painful physical symptoms in depression. J Clin Psychiatry. 2002;63:5.
139. Demyttenaere K, De Fruyt J, Stahl SM. The many faces of fatigue in major depressive disorder. Int J Neuropsychopharmacol. 2005;8:93-105.
140. Stahl SM, Briley M. Understanding pain in depression. Hum Psychopharmacol Clin Exp. 2004;19:9-13.
141. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry. 1997;54:597-606.
142. Duman RS, Malberg J, Thome J. Neural plasticity to stress and antidepressant treatment. Biol Psychiatry. 1999;46:1181-1191.
143. Dunn AJ, Swiergiel AH, de Beaurepaire R. Cytokines as mediators of depression: what can we learn from animal studies? Neurosci Biobehav Res. 2005;29:891-909.
144. Flores BH, Musselman DL, DeBattista C, Garlow Sed. J, Schatzberg AF, Nemeroff CB. Biology of mood disorders. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Publishing Textbook of Psychopharmacology, 3rd ed. Washington, DC, London, UK: American Psychiatric Publishing; 2004;717-763.
145. Gould E, Tanpat R, Rydel T, et al. Regulation of hippocampal neurogenesis in adulthood. Biol Psychiatry. 1999;48:715-720.
146. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27:24-31.
147. Ressler KJ. Pathophysiology of major depressive disorder. Monoamines, neuropeptides, and neurotrophins. Prim Care Companion J Clin Psychiatry. 2004;6:253-256.
148. Blackburn-Munro G. Hypothalamo-pituitary-adrenal axis dysfunction as a contributory factor to chronic pain and depression. Curr Pain Headache Reports. 2004;8:116-124.
149. Blackburn-Munro G, Blackburn-Munro RE. Chronic pain, chronic stress and depression: coincidence or consequence. J Neuroendocrinol. 2001;13:1009-1023.
150. Blackburn-Munro G, Blackburn-Munro R. Pain in the brain: are hormones to blame? Trends Endocrinol Metab. 2003;14:20-27.
151. Fava M. Somatic symptoms, depression and antidepressant treatment. J Clin Psychiatry. 2002;63:4.
152. Thase ME. Achieving remission and managing relapse in depression. J Clin Psychiatry. 2003; 64(suppl 18):3-7.
153. Fishbain DA. Relationship between physical symptoms and depression treatment response or resistence in patients with comorbid medical conditions. Prim Care Companion J Clin Psychiatry. 2005;7:288-290.
154. Lynch ME. Antidepressants as analgesics: a review of randomized controlled trials. J Psychiatry Neurosci. 2001;26:30-36.
155. Barkin RL, Barkin S. The role of venlafaxine and duloxetine in the treatment of depression with decremental changes in somatic symptoms of pain, chronic pain, and the pharmacokinetics and clinical considerations of duloxetine pharmacotherapy. Am J Therapeutics. 2005:12 (suppl 5):431-438.
156. Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry. 2001;62:869-877.
157. Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry. 2002;180:396-404.
158. Zajecka JM, Albano D. SNRIs in the management of acute major depressive disorder. J Clin Psychiatry. 2004;65(suppl 17):11-18.
159. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178:234-241.
160. Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res. 2005;39:43-53.
161. Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paraxetine-controlled trial. Eur Neuropsychopharmacol. 2004;14(suppl 6):457-470.
162. Fava M, Mallinckrodt CH, Detke MJ, Watkin JG, Wohlreich MM. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates. J Clin Psychiatry. 2004; 65(suppl 4):521-530.
163. Goldstein DJ, Lu Y, Detke MJ, Hudson J, Iyengar S, Demitrack MA. Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics. 2004. 45:17-28.
164. Vitton O, Gendreau M, Gendreau J, et al. A double-blind, placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol. 2004;19(suppl 1):S27-S37.
165. Schatzberg AF, Cole JO, DeBattista C. Manual of Clinical Psychopharmacology. 5th ed. Washington, DC, London, UK: American Psychiatric Publishing; 2005.
166. Fava M. Pharmacologic approaches to the management of residual symptoms in major depessive disorder. Prim Care Companion J Clin Psychiatry. 2004;6:256-258.
167. Hirschfeld RMA, Montgomery SA, Aguglia E, et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry. 2002;63:826-837.
168. Fava GA, Ruini C, Sonnino N. Treatment of recurrent depression. A sequential psychotherapeutic and psychopharmacological approach. CNS Drugs. 2003;17:1109-1117.
169. Thase ME. New approaches to severe and refractory depression. J Clin Psychiatry. 1999;60:629-630.